Cargando…
Omalizumab therapy in three patients with chronic autoimmune urticaria
Chronic urticaria is a common skin disease. In about 45% of patients the cause is an autoantibody directed at the α-subunit of the high-affinity IgE receptor (chronic autoimmune urticaria; CAU). Omalizumab is a monoclonal anti-IgE antibody that has a proven role in the treatment of various allergic...
Autor principal: | Al-Ahmad, Mona |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994167/ https://www.ncbi.nlm.nih.gov/pubmed/20864790 http://dx.doi.org/10.4103/0256-4947.70567 |
Ejemplares similares
-
Incapacitating solar urticaria: successful treatment with
omalizumab
por: Kieselova, Katarina, et al.
Publicado: (2019) -
Cyclosporine for omalizumab-refractory chronic urticaria: a report of five cases
por: LaCava, Anthony F., et al.
Publicado: (2023) -
Impact of Omalizumab on Anaphylaxis in Patients Treated for Chronic Urticaria
por: Song, Xiaoting, et al.
Publicado: (2023) -
Omalizumab in chronic spontaneous urticaria (CSU): experience in three cases
por: Valle, Solange Oliveira Rodrigues, et al.
Publicado: (2015) -
Effects of omalizumab on chronic urticaria not responding to recommended therapy
por: Hébert, Jacques, et al.
Publicado: (2012)